Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration

Martín, Daniel; Maguire, Maureen G.; Fine, Stuart L.; Ying, Gui‐Shuang; Jaffe, Glenn J.; Grunwald, Juan E.; Toth, Cynthia A.; Redford, Maryann; Ferris, Frederick L.

doi:10.1016/j.ophtha.2020.01.029

Cited by 251 publications

(371 citation statements)

References 0 publications

Supporting

Mentioning

325

Contrasting

Unclassified

Order By: Relevance

“…)) yielding the lowest ICER, followed by bevacizumab PRN (as in the CATT study (Martin et al. )); and monthly bevacizumab. Aflibercept; ranibizumab PRN; and monthly ranibizumab, yielded increasingly higher ICERs.…”

Section: Resultsmentioning

confidence: 97%

A systematic review on the quality, validity and usefulness of current cost‐effectiveness studies for treatments of neovascular age‐related macular degeneration

Elshout

Webers

Reis

et al. 2018

Acta Ophthalmologica

View full text Add to dashboard Cite

Two of the CEAs of sufficient quality and validity show that bevacizumab PRN is the most cost-effective treatment. Comparing ranibizumab and aflibercept, either treatment can be more cost-effective depending on the assumptions used for drug prices and treatment frequencies. The majority of the published CEAs are of insufficient quality and validity. They wrongly inform decision-makers at the cost of opportunities for ophthalmologists to treat patients. As such, they may negatively influence overall patient outcomes and societal costs. For future ophthalmic treatments, CEAs need to be improved and only published when they are of sufficient quality and validity.

show abstract

Section: Resultsmentioning

confidence: 97%

A systematic review on the quality, validity and usefulness of current cost‐effectiveness studies for treatments of neovascular age‐related macular degeneration

Elshout

Webers

Reis

et al. 2018

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…Treatment with bevacizumab as a cheaper, off‐label anti‐VEGF substitute for IVR was initially a bold choice for which large comparative trials were performed only recently (CATT Research Group et al. ; IVAN Study Investigators et al. ; Solomon et al ).…”

Section: Discussionmentioning

confidence: 99%

“…), and the efficacy of off‐label IVB compared to its on‐label counterpart (CATT Research Group et al. ; IVAN Study Investigators et al. ) has been well‐studied in recent years.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bevacizumab in age‐related macular degeneration: a randomized controlled trial on the effect of on‐demand therapy every 4 or 8 weeks

Amarakoon

Martinez-Ciriano

Born

et al. 2018

Acta Ophthalmologica

View full text Add to dashboard Cite

Purpose: Intravitreal anti-vascular endothelial growth factor (VEGF) injections are an effective treatment for neovascular age-related macular degeneration (nARMD). Bevacizumab appears to be a cost-effective off-label anti-VEGF alternative to ranibizumab, but an optimal injection schedule has not yet been determined. In this study, we investigate whether on-demand bevacizumab treatment every 8 weeks is non-inferior to on-demand bevacizumab every 4 weeks in treating nARMD. Methods: A total of 120 nARMD patients were randomly assigned to an ondemand regimen of intravitreal bevacizumab (IVB) every 4 (n = 60) or 8 weeks (n = 60). The primary outcome was visual acuity (VA) change after 1 year of treatment.Results: Visual acuity (VA) improved between baseline and 1 year in both treatment groups. The mean change in the VA score at 1 year was not significantly different between bevacizumab administration on-demand every 4 weeks [5.6 AE 10.2 Early Treatment Diabetic Retinopathy Study (ETDRS) letter] or 8 weeks (4.6 AE 12.0 ETDRS letters). A reduction in the central retinal thickness was observed in both groups. At 1 year, the mean decrease in central foveal thickness ranged from 61 AE 90 lm in the 4-week group to 91 AE 83 lm in the 8-week group (p = 0.07). The mean number of IVB treatments during the study period was 8.7 AE 2.3 in the 4-week group and 5.9 AE 1.0 in the 8-week group. Conclusion: At 1 year, bevacizumab administration on-demand every 8 weeks was non-inferior to administration every 4 weeks. The results strongly suggest that bevacizumab acts longer than 4 weeks in ARMD, reducing the burden of injections for patients.SWOO-Flieringa, Rotterdam; Stichting voor Ooglijders, Rotterdam; These funding organizations had no role in the design or conduct of this research.

show abstract

“…The advent of anti-vascular endothelial growth factor (VEGF) agents has improved treatment outcomes of CNV, with early detection and treatment resulting in favourable outcomes. [1][2][3] Currently, treatment decisions are mainly based on detection of neovascular activity using fluorescein angiography (FA) and optical coherence tomography (OCT). 4,5 However, interpretation of these two imaging modalities may be challenging in presence of fundus pathologies with scarring, atrophy and non-CNV-related intra-or subretinal fluid.…”

Section: Introductionmentioning

confidence: 99%

Retinal imaging including optical coherence tomography angiography for detecting active choroidal neovascularization in pseudoxanthoma elasticum

Birtel

Lindner

Mishra

et al. 2018

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

show abstract

Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration

Cited by 251 publications

References 0 publications

A systematic review on the quality, validity and usefulness of current cost‐effectiveness studies for treatments of neovascular age‐related macular degeneration

A systematic review on the quality, validity and usefulness of current cost‐effectiveness studies for treatments of neovascular age‐related macular degeneration

Bevacizumab in age‐related macular degeneration: a randomized controlled trial on the effect of on‐demand therapy every 4 or 8 weeks

Retinal imaging including optical coherence tomography angiography for detecting active choroidal neovascularization in pseudoxanthoma elasticum

Contact Info

Product

Resources

About